stock-detail (ONCS)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/24/2017 12:18 pm

4/21/2017 06:19 am

4/11/2017 12:17 pm

4/11/2017 12:17 pm

4/11/2017 12:17 pm

4/11/2017 12:17 pm

4/11/2017 06:17 am

OncoSec Presents Preclinical Data Demonstrating Improved Systemic Anti-Tumor Response Following Modifications to IL-12 Gene Delivery Therapy at AACR Annual Meeting

4/3/2017 12:00 pm

[PR Newswire] - SAN DIEGO, April 3, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented a poster titled "Intratumoral Delivery of a P2A-linked Bicistronic IL-12 Construct Leads to High Intratumoral Expression and Systemic Anti-tumor Response" (Abstract ID # 1614) at the American Association of Cancer Research (AACR) Annual Meeting, in Washington, D.C. The poster included preclinical data demonstrating the latest developments of OncoSec's gene delivery platform in a murine melanoma model. Previous studies have shown the use of immunomodulatory cytokines is effective in the regression of a wide range of tumors. Intratumoral gene electrotransfer of plasmid encoded interleukin-12 (IL-12) has shown acceptable safety and efficacy profiles in regressing tumors, both preclinically and clinically.

OncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017

3/28/2017 10:00 am

[PR Newswire] - SAN DIEGO, March 28, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present preclinical ...

OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models

3/21/2017 06:00 pm

[PR Newswire] - SAN DIEGO, March 21, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today presented a poster ...

OncoSec Announces First Technology Access Program Agreement with Inhibrx

3/14/2017 10:00 am

[PR Newswire] - SAN DIEGO, March 14, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that they ...

OncoSec to Present at Scientific and Investment Conferences in March

3/7/2017 02:02 pm

[PR Newswire] - SAN DIEGO, March 7, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will present preclinical ...

OncoSec to Host Second Quarter Financial Conference Call on March 16, 2017

3/2/2017 11:00 am

[PR Newswire] - SAN DIEGO, March 2, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that the ...

OncoSec Granted FDA Fast Track Designation for ImmunoPulse® IL-12 for the Treatment of Metastatic Melanoma Following Progression on Pembrolizumab or Nivolumab

2/27/2017 11:00 am

[PR Newswire] - SAN DIEGO, Feb. 27, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, received Fast Track designation ...

OncoSec to Host KOL Event Focused on New ASCO-SITC Melanoma Data and Clinical Strategy on Tuesday, February 28 in New York City

2/24/2017 11:00 am

[PR Newswire] - SAN DIEGO, Feb. 24, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, will host a Key Opinion Leader ...

OncoSec Announces Positive Phase II Data Demonstrating Company's ImmunoPulse® IL-12 in Combination with Pembrolizumab Increased Response Rates in Anti-PD-1 Non-Responder Melanoma Patients

2/23/2017 04:03 pm

[PR Newswire] - SAN DIEGO, Feb. 23, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today reported new positive ...